To scroll text in this page
![]()
Prograf® is an immunosuppressant used to prevent rejection in organ transplants. It is sold in about hundred countries around the world. Used by many transplant recipients in the United States, where organ transplant is widely performed, Prograf® has built an enduring position in transplant medicine.
![]()
Vesicare®, a treatment for overactive bladder, acts by blocking the muscarinic receptors in bladder smooth muscle to improve symptoms such as urinary frequency, urgency and urge incontinence associated with overactive bladders. Launched in Europe in 2004, it is now marketed in over seventy countries.
![]()
Protopic® is the world's first treatment for atopic dermatitis in the topical immunomodulator class. It reduces inflammation by inhibiting the body's production of cytokine and suppressing allergic responses. It is marketed in about seventy countries around the world.
![]()
(Flomax®, Omnic®, and Omnic OCAS® in the United States and Europe)
Harnal® is an α1 blocking agent with great selectivity for prostatic and urethral smooth muscle, to treat the functional symptoms of benign prostatic hyperplasia (BPH), including weak urinary stream, frequent nighttime urination, and sensation of incomplete emptying of the bladder. Now marketed in hundred countries around the world, it is the global standard in BPH treatment.
![]()
(Mycamine® in the United States and Europe)
A candin antifungal agent, Fungard® operates on a new mechanism, inhibiting synthesis of the fungus cell wall. It combines both outstanding clinical effectiveness and high safety. It is marketed in about forty countries around the world.